Bone Therapeutics

Bone Therapeutics is a Gosselies, Belgium-based biotechnology company that develops advanced cell therapy products for the repair and regeneration of bone and joint tissues. The organization targets severe orthopedic conditions and complex bone diseases through minimally invasive procedures, utilizing its proprietary clinical product pipeline that includes ALLOB, PREOB, and JTA-004 for knee osteoarthritis. Operating as a publicly traded entity in the healthcare sector, the firm has secured $31.91 million in total funding and completed a 2015 initial public offering that generated €37 million, currently maintaining a market capitalization of approximately $10 million. The company has established strategic development partnerships with Link Health and Pregene, while its executive leadership has included notable industry figures such as current chief executive officer Miguel Forte and former chief executive officer Enrico Bastianelli. Bone Therapeutics was officially founded in 2006.